CytomX Therapeutics, Inc.
CTMX
$3.36
$0.010.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -86.18% | 1,447.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -86.18% | 1,447.21% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -86.18% | 1,447.21% | |||
| SG&A Expenses | -28.91% | 70.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.81% | 16.03% | |||
| Operating Income | -20.89% | 21.73% | |||
| Income Before Tax | -13.29% | 31.25% | |||
| Income Tax Expenses | 1.69% | 9.26% | |||
| Earnings from Continuing Operations | -13.25% | 31.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.25% | 31.17% | |||
| EBIT | -20.89% | 21.73% | |||
| EBITDA | -22.21% | 21.12% | |||
| EPS Basic | 8.26% | 40.83% | |||
| Normalized Basic EPS | 8.27% | 26.41% | |||
| EPS Diluted | 8.26% | 41.23% | |||
| Normalized Diluted EPS | 8.27% | 26.41% | |||
| Average Basic Shares Outstanding | 23.50% | 4.47% | |||
| Average Diluted Shares Outstanding | 23.50% | 4.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||